drugset
drugset / Trial / NCT02649608

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

NCT02649608 ↗

Phase 1 Completed 15 enrolled H. Lundbeck A/S
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the safety, tolerability, pharmacokinetics, and efficacy of the Lu AE04621 and metabolite after ascending oral doses of Lu AE04621 in patients with Parkinson's Disease.

Timeline

Start
2016-01
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AE04621 Unknown 0.04 mg Oral
Subject Lu AE04621 Unknown 0.08 mg Oral
Subject Lu AE04621 Unknown 0.2 mg Oral
Subject Lu AE04621 Unknown 0.4 mg Oral
Subject Lu AE04621 Unknown 0.6 mg Oral
Subject Lu AE04621 Unknown 0.8 mg Oral
Subject Lu AE04621 Unknown 1 mg Oral
Subject Lu AE04621 Unknown 1.2 mg Oral

Indications

Parkinson disease